CN111686182A - 一种消瘀止痛中药组合物及其制备方法 - Google Patents
一种消瘀止痛中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN111686182A CN111686182A CN202010650855.4A CN202010650855A CN111686182A CN 111686182 A CN111686182 A CN 111686182A CN 202010650855 A CN202010650855 A CN 202010650855A CN 111686182 A CN111686182 A CN 111686182A
- Authority
- CN
- China
- Prior art keywords
- pain
- stasis
- relieving
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 76
- 210000004369 blood Anatomy 0.000 title claims abstract description 65
- 239000008280 blood Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 81
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000000052 vinegar Substances 0.000 claims abstract description 14
- 235000021419 vinegar Nutrition 0.000 claims abstract description 14
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 11
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 11
- 239000004863 Frankincense Substances 0.000 claims abstract description 10
- 241000239226 Scorpiones Species 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 9
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 9
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 9
- 241000258920 Chilopoda Species 0.000 claims abstract description 9
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 9
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 9
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 9
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 8
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 8
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract description 8
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 240000000233 Melia azedarach Species 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 241000213006 Angelica dahurica Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 abstract description 28
- 208000010392 Bone Fractures Diseases 0.000 abstract description 20
- 206010017076 Fracture Diseases 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 208000004880 Polyuria Diseases 0.000 abstract description 8
- 230000035619 diuresis Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000002110 toxicologic effect Effects 0.000 abstract description 3
- 231100000027 toxicology Toxicity 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 description 25
- 230000008961 swelling Effects 0.000 description 25
- 230000001737 promoting effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000125175 Angelica Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 231100001252 long-term toxicity Toxicity 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 206010072132 Fracture pain Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 206010010121 compartment syndrome Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000777488 Heteractis magnifica DELTA-stichotoxin-Hmg2b Proteins 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- NAHTXVIXCMUDLF-DUJPAFNYSA-N Toosendanin Natural products O=C(O[C@H]1C(=O)[C@H]2[C@@](C)([C@H](O)C[C@H]3[C@@]4(C)[C@H](O)OC[C@@]23[C@@H](O)C[C@H]4OC(=O)C)[C@@]23[C@]1(C)[C@H](c1cocc1)C[C@H]2O3)C NAHTXVIXCMUDLF-DUJPAFNYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- NAHTXVIXCMUDLF-RFNFAWMESA-N toosendanin Chemical compound C=1([C@H]2[C@]3(C)[C@@H](OC(C)=O)C(=O)[C@H]4[C@@]([C@@]53O[C@@H]5C2)(C)[C@H](O)C[C@H]2[C@@]3(C)[C@H](O)OC[C@]24[C@@H](O)C[C@H]3OC(=O)C)C=COC=1 NAHTXVIXCMUDLF-RFNFAWMESA-N 0.000 description 1
- 239000008488 toosendanin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于中医中药技术领域,公开了一种消瘀止痛中药组合物及其制备方法,所述的消瘀止痛中药组合物由当归10‑30g、丹参30‑60g、醋乳香10‑20g、醋没药10‑20g、延胡索30‑60g、川楝子10‑20g、茯苓10‑30g、白术10‑30g、泽泻10‑30g、陈皮10‑30g、酒大黄10‑20g、地龙10‑30g、全蝎10‑30g和蜈蚣10‑30g组成。本发明以“活血消瘀,利水消肿,通络止痛”为治疗法则,针对“骨折早期”消瘀、止痛,经多年临床观察,疗效好,副作用小,临床应用疗效显著,值得运用推广。本发明采用现代药学理论和手段研制其颗粒剂,进行临床前药学、药理毒理分析,力争开发成为医院院内复方制剂;不仅能产生可观的经济效益,还能带来良好的社会意义。
Description
技术领域
本发明属于中医中药技术领域,尤其涉及一种消瘀止痛中药组合物及其制备方法。
背景技术
目前,肢体骨折后多数患者会迅速出现肿胀疼痛,而肿胀疼痛的程度与手术时机的选择、骨折的愈合、皮肤的愈合、踝关节功能的恢复等有着密切的关系。骨折采用手术治疗或手法复位,都会出现一定程度的肢体肿胀,严重者影响动脉供血或产生静脉回流障碍,少数患者甚至会出现筋膜间室综合征,如不进行恰当的对症处理,就可能影响骨折的愈合以及功能的恢复。因此,尽早、尽快、有效地消除早期肿痛在骨折治疗过程中显得至关重要。如何加速软组织肿胀的消退、缩短术前消肿的周期,减轻疼痛程度,是目前国内外相关临床工作者探讨的热点话题。目前传统治疗方法主要包括中药外敷、内服、熏洗等。随着对中医药研究的深入,各种中药制剂的研制和开发,使传统的中药治疗溶入了现代科技术,在应用上更方便,作用机制也得到进一步的阐明,骨折早期肿胀的早期治疗手段也在原来内服、外敷、熏洗基础上多样化,使之更符合临床治疗的需要。通过临床考究发现,对于骨折后早期出现的肿痛,利水是关键,以“活血消瘀,利水消肿,通络止痛”为治疗法则,以“消瘀止痛方”随症加减,临床运用活血消肿方治疗骨折围手术期肿胀疼痛能收到良好的疗效。
祖国医学对本病病因多归属为“水肿”、“瘀血”、“骨断筋伤”等范围。《备急千金要方》中有较为详细的论述:“气滞,血行不畅,瘀滞于经脉,气血凝滞则痛,脉道阻塞则肿”。由此可看出,此类肿痛主要是由于瘀血、气滞引起的,骨断筋伤,血溢脉外,瘀积则肿,瘀阻气机,不通则痛。而《血证论》载述:“血与水本不相离,瘀血化水,亦发水肿,是血病而兼水也”。“血积既久,亦能化为痰水”的说法。“血不利而为水”,水多泛溢肌肤,聚积成湿,发为水肿,可见肿胀是体内津液输布出现异常所致。因此,骨折的肿胀疼痛的治疗,应从气血津液和脏腑经络出发,并注重整体观念,将病机概括为“气滞”、“血瘀”、“水蓄”、“痰湿”、“邪毒”等方面,但在病情变化中这些致病因素往往不是独立存在的,而是相互关联,相互影响。
中医“创伤骨科”奠基人蔺道人在《仙授理伤续断秘方》中详细论述了跌打损伤之肿痛主要是瘀血造成的,主张当以攻下逐瘀法治之,善用大黄、芒硝与活血化瘀药配伍使用,代表方剂如紫金汤和大小承气汤,治疗骨伤科瘀血之症得到了较明显的成效。清代叶天士关于瘀血致病,认为外感毒邪入里化热,易煎熬津液而致血瘀,当用凉血解毒,活血化瘀之法,临床上选用犀角地黄汤加桃仁、丹参参等药物。并提出“久病入络”的独特见解,主张活血化瘀通络的治法。临床用药时善用虫类逐瘀药物,如土鳖虫、水蛭等。《临证指南医案》中记载:“久病血瘀,瘀从便下”,提出活血同时兼以利水,使瘀血得以从小便排出。唐容川在《血证论》中载述,瘀血是由“离经之血”造成的,提出祛瘀生新的独特看法,强调祛瘀在生新中的重要性,在治则上提出“止血、消瘀、宁血、补血”四大原则,并对不同部位出现的瘀血运用不同的方剂治疗。
骨折后早期肢体肿胀疼痛为骨科常见症状,骨折采用手术治疗或手法复位,都会出现一定程度的肢体肿胀严重者影响动脉供血或静脉回流,少数患者甚至会出现筋膜间室综合征,如不进行恰当的对症处理,就可能影响骨折的愈合以及功能的恢复。消瘀止痛方中药内服法以中医理论为指导,根据具体病症,遵循辩证论治的原则,发挥局部,甚至是整体的治疗作用,使腠理疏通,气血调和,阴阳平衡,从而达到预防和治疗疾病的目的。但是剂型存在制剂困难、储存困难、携带不便,口感不佳等不足。传统剂型多采用煎汤带水,且多由不懂中药制备专业知识的患者承担了大部分专业性极强的汤剂煎煮工作,采用制备汤剂的器具不当;煎煮时间、煎煮加水量不当;煎煮火候及煎煮次数失当,从而直接影响疗效,导致制剂困难。煎煮后汤剂一般当日服用,最多保存3天左右,否则易腐烂变质,导致储存困难。且汤剂煎煮后一般由家庭用容器存储,携带不便。消瘀止痛方多由辛苦味药物组成,服用口感不佳。经过颗粒制备,提取有效成分,统一使用包装袋密封包装,使用时只需用热开水泡即可服用,既保证了疗效,又解决了上述存在问题。
现有技术公开以下方案:
第一步,浸泡:以当归15g、丹参30g、醋乳香10g、醋没药10g、延胡索30g、川楝子10g、茯苓15g、白术10g、泽泻15g、陈皮15g酒大黄5g,以冷水浸泡,水量以没过药物一横指或2厘米左右为宜,浸泡约20~30分钟,可使药物***,细胞壁膨胀,药物的有效成分容易渗透到水分中。
第二步,煎煮:①将以上浸泡药物放入砂锅内,加入清水,观察加水能否浸满药面,不足时可稍加水量。水的用量一般为:第一遍煎煮时为药材量的5-8倍,或将饮片适当加压后,液面淹没过饮片约2厘米为宜。第二遍用水量可少一些。②先用猛火煎至充分沸腾1-3分钟。然后收至小火,煎20-30分钟,头煎结束后,将药汁滤出,重新加水至高出药平面约0.5-1厘米(最好不冷水,用热水,因为加冷水会使原来已经膨胀疏松的药材组织发生皱缩,降低了有效成分的煎出,降低了疗效)。继续武火煎煮至沸腾后改为文火煎煮15-20分钟即可。③汤剂煎完后应榨渣取汁。趁热将药液滤出后,要将药渣用双层纱布包好,绞取药渣内剩余药液。有研究表明绞取药渣内的药液可增加药液成份的l5%~25%。④药液煎取量:前后两次煎煮取汁450ml。
第三步,另服:以地龙10g、全蝎10g和蜈蚣10g打成散剂,等分为三份。第四步,服用方法:每日一剂,每次取150ml,温服,饭后服,服用时加入一等份散剂(地龙、全蝎、蜈蚣)。每次煎煮时,夏天不超过3付,冬天不超过5付。
第五步,储存:冬季可常温下储存,夏季需放入冰箱处冷藏。
综上所述,现有技术存在的问题是:剂型存在储存困难、携带不便,口感不佳。传统中药煎煮法在实际操作中,要通过浸泡、一煎、二煎,约需要90分钟才能完成1剂中药的煎制。在煎煮过程中,要注意特殊药物的先煎、后下,文、武火的变换,要不断搅拌中药,防止糊底和药液溢出,操作繁琐,药液中挥发性成分容易损失,一般家庭煎煮,只能煎煮40%-70%的有效成分,药用资源造成大量的隐性浪费,从而降低了药物临床疗效。中药由于体积较大,仓储所占面积较大,费工费时,如保管不当易引起的走油、发霉、虫蛀等问题。
解决上述技术问题的难度:目前现有技术无专门针对骨折早期消肿止痛的复方颗粒,为取得复方颗粒需有相关专业技术人员及设备。
解决上述技术问题的意义:本发明以“消瘀止痛方”组方入手,采用现代药学理论和手段研制其颗粒剂,进行临床前药学、药理毒理分析,力争2-3年开发成为医院院内复方制剂。复方制剂的好处在于既能保证有效成份,有可以使患者方便服用,不仅能产生可观的经济效益,增加收入;还能带来良好的社会意义,使中医药事业继续向前发展。
众多中医工作者在临床上应用中药配方颗粒治疗疾病时,本发明进行了大量临床观察,结果表明中药配方颗粒疗效显著,与传统汤剂相比基本一致,甚至要优于传统汤剂。
发明内容
针对现有技术存在的问题,本发明提供了一种消瘀止痛中药组合物及其制备方法。
本发明是这样实现的,一种消瘀止痛中药组合物由当归10-30g、丹参30-60g、醋乳香10-20g、醋没药10-20g、延胡索30-60g、川楝子10-20g、茯苓10-30g、白术10-30g、泽泻10-30g、陈皮10-30g、酒大黄10-20g、地龙10-30g、全蝎10-30g和蜈蚣10-30g组成。
全方以当归、丹参活血化瘀,通络止痛,兼以养血;配伍乳香、没药、延胡索、川楝子、地龙、全蝎蜈蚣以增强活血行气,消肿定痛之效。辅以陈皮、白术、茯苓、泽泻、酒大黄以健脾理气、利水渗湿。现代药理研究显示,当归含有阿魏酸钠等,丹参含有丹参酮、丹酚酸等,乳香、没药含有乳香脂酸、阿魏酸钠、树脂、树胶等,具有明显的抗炎镇痛,改善微循环及血液流变,降低全血黏度、血浆黏度,抑制抗血小板黏附、活化、聚集,改善血液循环等作用。延胡索、川楝子含有延胡索碱及延胡索乙素、川楝素等,具有强烈的镇静、镇痛、抗炎等作用,且无成瘾性。全蝎主要含有蝎毒素,对皮肤痛、内脏痛具有显著的镇痛作用,能激活凝血酶,降低抗凝血酶及纤溶酶原含量,具有抗血栓、抗凝及促纤溶作用。地龙含有不包含脂肪酸、蛋白质及核苷酸等,具有抗炎消肿、抗血栓,改善血液循环等功效。蜈蚣含有组胺样物质及溶血性蛋白质,具有明显的镇静、止痉等作用。茯苓、白术、泽泻、陈皮、酒大黄含有β-茯苓聚糖、苍术酮及白术内酯A/B、三萜及倍半萜类成分、橙皮苷及川陈皮素、大黄酸及大黄素等,具有利尿、消肿、镇静、解痉等作用。
本发明的另一目的在于提供一种消瘀止痛中药组合物的制备方法,具体包括以下步骤:
步骤一:加10倍药材水量,浸泡0.5h,煎煮1h,过滤药渣,药渣再加入8倍重量的水,煎煮1h的方式,是为了得到煎煮原液,而通常中药原液熬制需分两次熬制所得的液体,才能利于药效的充分释放。
步骤二:在中药制剂生产过程中,多采用乙醇作为中药材有效成份提取溶剂,在醇含量达75%最利于中药有效成分的提取。在乙醇提取结束后的乙醇回收是一道非常重要的工序。在浓缩至60℃相对密度为1.25时,可以保障乙醇回收率,实现乙醇的重复使用和最大限度地循环利用,减少浪费和环境污染。
步骤三:本品为复方,成分复杂,其提取液是液是真溶液、胶体、悬浊及乳浊液的混合体。经步骤二的浓缩至1.25的相对密度后,利用喷雾干燥可形成细颗粒状的成品即为复发颗粒剂。为保持喷雾干燥的稳定状态、保持浓缩液的粘度,需要进风温度为100℃,出风温度为90℃,物料温度为70℃,雾化液压为0.2兆帕,喷雾速度为10ml/s。
步骤四:经过上述步骤后,可得到状态稳定、粘度适中的复发颗粒制剂。
综上所述,本发明的优点及积极效果为:
组别 | u | 轻度疼痛 | 中度疼痛 | 重度疼痛 | 轻度水肿 | 中度水肿 | 重度水肿 |
口服中药组 | 150 | 140 | 10 | 0 | 146 | 4 | 0 |
西药组 | 150 | 126 | 22 | 2 | 135 | 10 | 5 |
中药+西药组 | 150 | 142 | 8 | 0 | 148 | 2 | 0 |
由上表可见,口服中药组轻度疼痛为93.3%,中度疼痛为7.7%,无重度疼痛;轻度水肿为97.3%,中度水肿为3.7%,无重度水肿。西药组轻度疼痛为84%,中度疼痛为14.6%,重度疼痛为1.4%;轻度水肿为90%,中度水肿为6.6%,重度疼痛为4.4%。中药+西药组轻度疼痛为94.6%,中度疼痛为75.4%,轻度水肿为98.6%,中度水肿为1.4%。本发明治疗对于骨折早期疼痛及水肿的治疗优于单纯使用西药脱水机组。
本发明以“活血消瘀,利水消肿,通络止痛”为治疗法则,针对“骨折早期”消瘀、止痛,经多年临床观察,疗效好,副作用小,临床应用疗效显著,值得运用推广。本发明以“消瘀止痛方”组方入手,采用现代药学理论和手段研制其颗粒剂,进行临床前药学、药理毒理分析,力争开发成为医院院内复方制剂;不仅能产生可观的经济效益,还能带来良好的社会意义。
附图说明
图1是本发明实施例提供的消瘀止痛中药组合物的制备方法流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明实施例提供的消瘀止痛中药组合物由当归10-30g、丹参30-60g、醋乳香10-20g、醋没药10-20g、延胡索30-60g、川楝子10-20g、茯苓10-30g、白术10-30g、泽泻10-30g、陈皮10-30g、酒大黄10-20g、地龙10-30g、全蝎10-30g和蜈蚣10-30g组成。
下面结合附图对本发明的应用原理作详细说明;
如图1所示,本发明实施例提供的消瘀止痛中药组合物的制备方法,具体包括以下步骤:
S101:取当归15g、丹参30g、醋乳香10g、醋没药10g、延胡索30g、川楝子10g、茯苓15g、白术10g、泽泻15g、陈皮15g、酒大黄5g、地龙10g、全蝎10g和蜈蚣10g,加药材10倍重量的水,浸泡0.5h,煎煮1h,过滤药渣,药渣再加入8倍重量的水,煎煮1h;
S102:合并两次煎煮液,减压浓缩至60℃相对密度为1.05,加乙醇,使醇含量的体积百分比达75%。搅拌、静置、过滤,滤液减压浓缩至60℃相对密度为1.25,并回收乙醇,得浓缩液;
S103:将浓缩液喷雾干燥,喷雾干燥条件为:进风温度为100℃,出风温度为90℃,物料温度为70℃,雾化液压为0.2兆帕,喷雾速度为10ml/s,添加淀粉50g;
S104:制粒,即得复方颗粒剂。
下面结合具体实施例及实验分析对本发明作进一步描述。
本发明实施例提供的急性毒性为:
根据选用急性毒性试验的方法,合理进行实验动物的分组。一般情况下,除设受试物的不同剂量组外,需要设立空白对照组和/或溶媒对照组。一般为14天,如果毒性反应出现较慢,应适当延长观察时间。
应测定LD50或最大耐受量。观察的指标包括一般指标(如动物外观、行为、对刺激的反应、分泌物、***物等)、动物死亡情况(死亡时间、濒死前反应等)、动物体重变化(给药前、试验结束处死动物前各称重一次,观察期间可多次称重)等。记录所有的死亡情况、出现的症状,以及症状起始的时间、严重程度、持续时间等。对濒死及死亡动物应及时进行大体解剖,其他动物在观察期结束后进行大体解剖,当发现器官出现体积、颜色、质地等改变时,则对改变的器官进行组织病理学检查。
本发明实施例提供的长期毒性为:
动物选择原则:推荐长期毒性试验采用啮齿类动物如大鼠,一般选择健康、体重均匀的动物,雌性应未孕。原则上,动物应雌雄各半。一般情况下,大鼠为6-9周龄;每组动物的数量应能够满足试验结果的分析和评价的需要。一般大鼠可为雌、雄各10-30只。
给药途径:原则上应与临床用药途径相同。
给药频率:原则上应每天给药,且每天给药时间相同。试验周期长(3个月或以上)者,也可采取每周给药6天。
给药期限:长期毒性试验给药期限的长短,通常与拟定的临床疗程长短、临床适应症、用药人群相关,应充分考虑预期临床的实际疗程。当受试物预期会长期使用,或用于反复发作性疾病等而需经常反复给药时,应进行大鼠6个月的长期毒性试验;其余应进行大鼠3个月的长期毒性试验。
给药剂量:一般情况下,至少应设3个剂量组和溶媒或赋形剂对照组,必要时还需设立空白对照组和/或阳性对照组。
检测指标:病理指标应尽量检测多脏器,但如有合理的理由说明所申报的医院制剂有一定的安全性,所检查的脏器和组织可减少为:心、肝、脾、肺、肾、脑、胃、小肠、大肠、垂体、脊髓、骨髓、***、膀胱、睾丸、附睾、子宫、卵巢、胸腺、肾上腺及给药局部组织等。
下面结合药理学分析对本发明的应用原理进行进一步说明;
消瘀止痛方,为活络消灵丹参和五苓散加减而成。本方用当归活血养血;丹参参助当归活血祛瘀,并可补养血分;乳香、没药行气止痛,活血祛瘀。四药合用,使瘀去络通,则疼痛自止,为治疗跌打损伤,瘀血肿痛之基础。《内经·灵兰秘典论》:“膀胱者,州都之官,津液藏焉,气化则能出矣”。《内经·至真要大论》:“诸湿肿满,皆属于脾”。“淡味渗泄为阳”,以猪苓、茯苓二药甘淡入肺而通膀胱;“咸味涌泄为阴”,泽泻甘咸入肾膀胱,同利水道;“益土所以制水”,故以白术苦温,健脾去湿。该方“活血消瘀,利水消肿,通络止痛”为治疗法则,针对“骨折早期”消瘀、止痛,经多年临床观察,疗效好,副作用小,临床应用疗效显著,值得运用推广。
下面结合具体实施例对本发明的应用原理进行进一步说明;
实施例1;
组别 | u | 轻度疼痛 | 中度疼痛 | 重度疼痛 | 轻度水肿 | 中度水肿 | 重度水肿 |
口服中药组 | 150 | 140 | 10 | 0 | 146 | 4 | 0 |
西药组 | 150 | 126 | 22 | 2 | 135 | 10 | 5 |
中药+西药组 | 150 | 142 | 8 | 0 | 148 | 2 | 0 |
对入院骨折患者进行编号,按照奇、偶数随机分为三组,即为口服中药组(试验组)和、西药组(对照组)及中药组+西药组(对照组)。中药组:入院口服活血消肿方,1付/d,150ml/次,tid;西药组:静脉输入甘油果糖,记录各组患者治疗前后肢体肿胀程度及疼痛数值。由上表可见,口服中药组轻度疼痛为93.3%,中度疼痛为7.7%,无重度疼痛;轻度水肿为97.3%,中度水肿为3.7%,无重度水肿。西药组轻度疼痛为84%,中度疼痛为14.6%,重度疼痛为1.4%;轻度水肿为90%,中度水肿为6.6%,重度疼痛为4.4%。中药+西药组轻度疼痛为94.6%,中度疼痛为75.4%,轻度水肿为98.6%,中度水肿为1.4%。本方治疗对于骨折早期疼痛及水肿的治疗优于单纯使用西药脱水机组。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种消瘀止痛中药组合物,其特征在于,所述的消瘀止痛中药组合物由当归10-30g、丹参30-60g、醋乳香10-20g、醋没药10-20g、延胡索30-60g、川楝子10-20g、茯苓10-30g、白术10-30g、泽泻10-30g、陈皮10-30g、酒大黄10-20g、地龙10-30g、全蝎10-30g和蜈蚣10-30g组成。
2.一种如权利要求1所述消瘀止痛中药组合物的制备方法,其特征在于,所述消瘀止痛中药组合物的制备方法,具体包括以下步骤:
步骤一:取当归15g、丹参30g、醋乳香10g、醋没药10g、延胡索30g、川楝子10g、茯苓15g、白术10g、泽泻15g、陈皮15g、酒大黄5g、地龙10g、全蝎10g和蜈蚣10g,加药材10倍重量的水,浸泡,煎煮,过滤药渣,药渣再加入水,煎煮;
步骤二:合并两次煎煮液,减压浓缩,加乙醇,使醇含量的体积百分比达75%;搅拌、静置、过滤,滤液减压浓缩至60℃相对密度为1.25,并回收乙醇,得浓缩液;
步骤三:将浓缩液喷雾干燥,添加淀粉50g;
步骤四:制粒,即得复方颗粒剂。
3.如权利要求2所述的消瘀止痛中药组合物的制备方法,其特征在于,所述步骤一中加药材10倍重量的水,浸泡0.5h,煎煮1h,过滤药渣,药渣再加入8倍重量的水,煎煮1h。
4.如权利要求2所述的消瘀止痛中药组合物的制备方法,其特征在于,所述步骤二中减压浓缩至60℃相对密度为1.05,加乙醇,使醇含量的体积百分比达75%。
5.如权利要求2所述的消瘀止痛中药组合物的制备方法,其特征在于,所述步骤三中喷雾干燥条件为:进风温度为100℃,出风温度为90℃,物料温度为70℃,雾化液压为0.2兆帕,喷雾速度为10ml/s。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010650855.4A CN111686182B (zh) | 2020-07-08 | 2020-07-08 | 一种消瘀止痛中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010650855.4A CN111686182B (zh) | 2020-07-08 | 2020-07-08 | 一种消瘀止痛中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111686182A true CN111686182A (zh) | 2020-09-22 |
CN111686182B CN111686182B (zh) | 2022-09-16 |
Family
ID=72485090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010650855.4A Expired - Fee Related CN111686182B (zh) | 2020-07-08 | 2020-07-08 | 一种消瘀止痛中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111686182B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127253A (zh) * | 2013-03-15 | 2013-06-05 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗骨折瘀血症的中药胶囊及其制备方法 |
CN103142737A (zh) * | 2013-03-15 | 2013-06-12 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗骨折气滞血瘀症的中药胶囊及其制备方法 |
CN109758514A (zh) * | 2019-03-22 | 2019-05-17 | 潘普选 | 一种用于止痛的中药组合物及其制备方法 |
CN110876788A (zh) * | 2019-09-26 | 2020-03-13 | 遵义红花岗刘端方医院(普通合伙) | 一种活血止痛中药药物及其制备方法 |
-
2020
- 2020-07-08 CN CN202010650855.4A patent/CN111686182B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127253A (zh) * | 2013-03-15 | 2013-06-05 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗骨折瘀血症的中药胶囊及其制备方法 |
CN103142737A (zh) * | 2013-03-15 | 2013-06-12 | 贵州省黔南布依族苗族自治州中医医院 | 一种治疗骨折气滞血瘀症的中药胶囊及其制备方法 |
CN109758514A (zh) * | 2019-03-22 | 2019-05-17 | 潘普选 | 一种用于止痛的中药组合物及其制备方法 |
CN110876788A (zh) * | 2019-09-26 | 2020-03-13 | 遵义红花岗刘端方医院(普通合伙) | 一种活血止痛中药药物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
华浩明: "《中医骨伤科处方手册》", 30 November 2006, 科学技术文献出版社 * |
周德生: "《中医膏方临床应用指南》", 30 November 2015, 山西科学技术出版社 * |
康金平: "中医药治疗骨折研究进展", 《中医药临床杂志》 * |
张琦: "《《金匮要略》理论与实践》", 30 April 2017, 中国中医药出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN111686182B (zh) | 2022-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091203B (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
CN103405582A (zh) | 改善类风湿关节炎关节肿痛的中药组合物 | |
CN102631538B (zh) | 一种治疗心脏病的中药 | |
CN101007157A (zh) | 一种治疗慢性胆囊炎的中药复方制剂 | |
CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
CN103599263B (zh) | 一种用于痔疮的中药及其制备方法 | |
CN111686182B (zh) | 一种消瘀止痛中药组合物及其制备方法 | |
CN104873948A (zh) | 一种治疗血管穿刺引起动脉血栓的中药制剂及其制备方法 | |
CN104547798A (zh) | 一种治疗慢性肠炎、阑尾炎的中药制剂及其制备方法 | |
CN104383050B (zh) | 一种内外结合治疗风湿性关节炎的药物及制备方法 | |
CN103860977B (zh) | 一种治疗皮炎的药物组合物 | |
CN103623122B (zh) | 一种用于痔疮的中药及其制备方法 | |
CN105169278A (zh) | 一种保肝利胆的蒲公英口服液及其制备方法 | |
CN102784311B (zh) | 一种治疗妇女产后病的中药组合物及其制备方法 | |
CN105456924A (zh) | 含有艾叶的具有活血化瘀功能的中药制剂及其制备方法 | |
CN105920379A (zh) | 一种缓解眼袋的中药眼霜及其制备方法 | |
CN105169294A (zh) | 一种治疗肩关节周围炎的中药膏剂 | |
CN105267711A (zh) | 一种用于治疗眩晕症的药物制剂 | |
CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
CN104721631A (zh) | 一种促进伤口愈合的中药组合物及其制备方法 | |
CN104645247B (zh) | 一种治疗肝豆状核变性的中药制剂及其制备方法 | |
CN108543038B (zh) | 一种化瘀止血的中药组合物及其制备方法和应用 | |
CN105456447A (zh) | 一种含有艾叶的具有活血化淤功能的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220916 |